[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625260":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":10,"locations":19,"responsibleParty":39,"collaborators":10,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":10,"eligibilityCriteria":46,"healthyVolunteers":47,"sex":48,"minAge":49,"maxAge":10,"enrollmentInfo":50,"targetDuration":53,"studyType":54,"phases":10,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":22,"whyStopped":10,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Technical University of Munich","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with depressive Syndrom receiving regular iTBS treatment",null,"Patients with depressive Syndrom receiving regular iTBS treatment over 4 weeks, no relevant personality disorder",[13],"Other: iTBS Treatment",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"iTBS Treatment","20 iTBS sessions over 4 weeks, lDLPFC (BeamF3), 600Pulses.",[9],[20],{"facility":21,"status":22,"city":23,"state":10,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"University Hospital Technical University of Munich","RECRUITING","München","81675","Germany","DE",{"type":28,"coordinates":29},"Point",[30,31],13.31243,51.60698,{"lat":31,"lon":30},[34],{"name":35,"role":36,"phone":37,"phoneExt":10,"email":38},"Ulrike Vogelmann, MD","CONTACT","+498941406882","ulrike.vogelmann@mri.tum.de",{"type":40,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100625260","real-world-neuromodulate-investigating-non-invasive-brain-stimulation-for-neuropsychiatric-disorders-at-tum-100625260",false,"NCT07420322","Real-World NeuroModulate: Investigating Non-Invasive Brain Stimulation for Neuropsychiatric Disorders at TUM","Inclusion Criteria:\n\nAge 18 years or older\n\nClinical indication for non-invasive brain stimulation due to a depressive episode (e.g., unipolar or bipolar depression) or predominant depression-associated symptoms (e.g., negative symptoms in schizophrenia-spectrum disorders)\n\nInsufficient response to first-line treatments and\u002For patient preference for brain stimulation treatment\n\nCapacity and willingness to provide written informed consent\n\nExclusion Criteria:\n\nAcute suicidal risk\n\nPresence of a significant neurological disorder or condition, including:\n\nIncreased intracranial pressure\n\nSpace-occupying brain lesions\n\nHistory of cerebrovascular accident within the last 12 months\n\nIncidental structural brain abnormalities on MRI requiring further diagnostic clarification\n\nFor TMS specifically:\n\nNon-removable ferromagnetic implants in or near the stimulation site (e.g., cochlear implants, implanted neurostimulators, metallic clips or nails)\n\nOther treatment-relevant ferromagnetic implants (e.g., cardiac pacemakers)",true,"ALL","18 Years",{"count":51,"type":52},100,"ESTIMATED","4 Months","OBSERVATIONAL","In this study, patients diagnosed with a depressive syndrome and with a clinical indication for treatment will receive an acute course of transcranial magnetic stimulation (TMS). The treatment consists of 20 TMS sessions administered over a period of four weeks (five sessions per week).\n\nMagnetic resonance imaging (MRI) will be performed at four time points: prior to the start of treatment, after 10 treatment sessions, after completion of all 20 sessions, and at a three-month follow-up after the end of treatment. The MRI data will include different imaging modalities to assess treatment-related neurobiological changes.\n\nThe primary objective is to investigate changes in neuroimaging markers over the course of TMS treatment and to examine their associations with clinical response and behavioral as well as clinical outcome measures. Another key goal of the study is the identification of markers allowing for early prediction of treatment response to TMS and, additionally, for the prediction of relapse at follow-up.",[57],"Depressive Syndrom",[59,60,61,62,63],"Depressive Disorder","TMS","rTMS","iTBS","MRI","2026-02-12",{"date":66,"type":67},"2026-02-19","ACTUAL",{"date":69,"type":67},"2024-08-15",{"date":71,"type":52},"2026-08-15",{"name":5,"class":6},1]